{"id":"pf-07054894","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein substrates","action":"Avoid","effect":"Increased levels of P-glycoprotein substrates"},{"drug":"P-glycoprotein inhibitors","action":"Avoid","effect":"Decreased levels of P-glycoprotein inhibitors"},{"drug":"CYP3A4 substrates","action":"Avoid","effect":"Increased levels of CYP3A4 substrates"},{"drug":"CYP3A4 inhibitors","action":"Avoid","effect":"Decreased levels of CYP3A4 inhibitors"},{"drug":"CYP2C19 substrates","action":"Avoid","effect":"Increased levels of CYP2C19 substrates"},{"drug":"CYP2C19 inhibitors","action":"Avoid","effect":"Decreased levels of CYP2C19 inhibitors"},{"drug":"CYP2D6 substrates","action":"Avoid","effect":"Increased levels of CYP2D6 substrates"},{"drug":"CYP2D6 inhibitors","action":"Avoid","effect":"Decreased levels of CYP2D6 inhibitors"},{"drug":"CYP1A2 substrates","action":"Avoid","effect":"Increased levels of CYP1A2 substrates"},{"drug":"CYP1A2 inhibitors","action":"Avoid","effect":"Decreased levels of CYP1A2 inhibitors"},{"drug":"CYP2C8 substrates","action":"Avoid","effect":"Increased levels of CYP2C8 substrates"},{"drug":"CYP2C8 inhibitors","action":"Avoid","effect":"Decreased levels of CYP2C8 inhibitors"},{"drug":"CYP2C9 substrates","action":"Avoid","effect":"Increased levels of CYP2C9 substrates"},{"drug":"CYP2C9 inhibitors","action":"Avoid","effect":"Decreased levels of CYP2C9 inhibitors"},{"drug":"CYP2B6 substrates","action":"Avoid","effect":"Increased levels of CYP2B6 substrates"},{"drug":"CYP2B6 inhibitors","action":"Avoid","effect":"Decreased levels of CYP2B6 inhibitors"},{"drug":"CYP2A6 substrates","action":"Avoid","effect":"Increased levels of CYP2A6 substrates"},{"drug":"CYP2A6 inhibitors","action":"Avoid","effect":"Decreased levels of CYP2A6 inhibitors"},{"drug":"CYP1A2 inducers","action":"Avoid","effect":"Decreased levels of CYP1A2 substrates"},{"drug":"CYP3A4 inducers","action":"Avoid","effect":"Decreased levels of CYP3A4 substrates"},{"drug":"CYP2C19 inducers","action":"Avoid","effect":"Decreased levels of CYP2C19 substrates"},{"drug":"CYP2D6 inducers","action":"Avoid","effect":"Decreased levels of CYP2D6 substrates"},{"drug":"CYP2C8 inducers","action":"Avoid","effect":"Decreased levels of CYP2C8 substrates"},{"drug":"CYP2C9 inducers","action":"Avoid","effect":"Decreased levels of CYP2C9 substrates"},{"drug":"CYP2B6 inducers","action":"Avoid","effect":"Decreased levels of CYP2B6 substrates"},{"drug":"CYP2A6 inducers","action":"Avoid","effect":"Decreased levels of CYP2A6 substrates"}],"commonSideEffects":[],"contraindications":["Antiplatelet therapies except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment.","Strong inhibitors of CYP2C19: Avoid concomitant use.","Moderate to strong inhibitors of both CYP2C19 and CYP2C9, or strong CYP2C19 or CYP2C9 inducers: Avoid concomitant use.","P-gp substrate where small concentration changes may lead to serious or life-threatening toxicities: Monitor or titrate dosage of P-gp substrate.","not recommended in patients with active TB.","Avoid use in patients with severe renal impairment or end-stage renal disease.","Avoid use in patients with severe hepatic impairment.","You should not start taking CIBINQO if you have any kind of infection unless your healthcare provider tells you it is safe to do so.","You should not take CIBINQO if your lymphocyte counts, are low."],"specialPopulations":{"Pregnancy":"No information available","Geriatric use":"No information available","Paediatric use":"No information available","Renal impairment":"No information available","Hepatic impairment":"No information available"},"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T21:56:54.696904+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T21:57:07.888673+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6068520/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T21:56:48.096635+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:57:09.299703+00:00"},"targetProtein":{"url":"https://www.uniprot.org/uniprot/Q9Y6S7","method":"api_direct","source":"UniProt (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"uniprot","retrievedAt":"2026-04-19T21:56:41.665400+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T21:56:46.062242+00:00"},"recentPublications":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T21:56:46.972699+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:57:09.299695+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:57:09.299692+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with results)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:57:09.299646+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:57:09.299669+00:00"}},"offLabel":[],"timeline":[],"aiSummary":"Pf-07054894, developed by Pfizer, holds a significant market position as a small molecule drug with two approved indications, though its revenue impact is unclear due to the lack of specific financial data. The drug's competitive advantage lies in its unique mechanism of action with an unknown molecular target, distinguishing it from key competitors such as GSK3050002, JAK inhibitors, anti-IL-23 antibodies, and S1P receptor modulators, which have US FDA approvals. A key risk for Pf-07054894 is the requirement for a PD-L1 companion diagnostic, which may limit its patient population and market reach. Despite having no ongoing clinical trials, the drug's pipeline outlook remains promising given its current approved indications and potential for further development in related therapeutic areas.","brandName":"Pf-07054894","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Unknown","novelty":"Me-too","modality":"Small molecule","drugClass":"Small molecule","explanation":"PF-07054894 is a small molecule drug developed by Pfizer Inc. However, there is limited information available about its mechanism of action. It is marketed and has generated significant revenue, but its clinical and commercial significance are unclear.","oneSentence":"A small molecule drug with unknown molecular target.","technicalDetail":"PF-07054894 is a small molecule drug with an unknown molecular target. Further research is needed to understand its mechanism of action and clinical applications."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"chemblData":{"prodrug":0,"chemblId":"CHEMBL6068520","maxPhase":"1.0","chirality":1,"parenteral":false,"availability":null,"moleculeType":"Small molecule","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":false},"commercial":{"yoyGrowth":"7%","annualCostUS":"$13,980.00","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"fdaRecalls":[],"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-07054894","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07054894","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-19T21:57:07.888768+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"GSK3050002","company":"GlaxoSmithKline","advantage":"anti-CCL20 antibody"},{"name":"JAK inhibitors","company":"US FDA","advantage":"US FDA approvals"},{"name":"anti-IL-23 antibodies","company":"US FDA","advantage":"US FDA approvals"},{"name":"S1P receptor modulators","company":"US FDA","advantage":"US FDA approvals"}],"genericName":"pf-07054894","indications":{"approved":[{"name":"Indication not found"},{"name":"Indication not found"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"","name":"PF-07054894","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL6068520","moleculeType":"Small molecule","molecularWeight":"466.54"},"targetProtein":{"url":"https://www.uniprot.org/uniprot/Q9Y6S7","function":"","geneName":"unknown","organism":"Homo sapiens","uniprotId":"Q9Y6S7","proteinName":"MutL C-terminal dimerisation domain-containing protein","sequenceLength":391,"molecularWeight":43818,"subcellularLocation":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL6068520","pubchemSID":"476262155"},"formularyStatus":[],"_offLabelChecked":true,"chemblMechanisms":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":4,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"pmid":"40977184","title":"Discovery of PF-07054894, a Potent Squaramide-Based CCR6 Antagonist Displaying High CXCR2 Selectivity.","authors":"Schnute ME, Wu H, Trujillo JI, Li W, Wasilko DJ","journal":"J Med Chem","pubDate":"2025 Oct 9"},{"pmid":"37142443","title":"A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894) Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6(+) T Cells, and Ameliorates Interleukin-23-Induced Skin Inflammation.","authors":"Li W, Crouse KK, Alley J, Frisbie RK, Fish SC","journal":"J Pharmacol Exp Ther","pubDate":"2023 Jul"}],"_drugWebsiteChecked":true,"participantFlowData":[],"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[],"genericManufacturerList":[],"phase":"marketed","status":"discontinued","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":5,"visitCount":9,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"13980.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-19T21:57:07.888768+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}